Stay updated on Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Sign up to get notified when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.

Latest updates to the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedLocations section expanded with new site locations across the United States, Canada, and Europe. The HHS Vulnerability Disclosure entry was removed.SummaryDifference2%

- Check21 days agoNo Change Detected
- Check28 days agoNo Change Detected
- Check42 days agoChange DetectedPublications section now includes a note that publications are automatically filled from PubMed. The revision label changed to v3.3.2 and the older PubMed note and revision (v3.2.0) were removed; To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.1%

- Check50 days agoChange DetectedThe funding-status notice banner was removed from the page, reducing banner clutter without affecting the study details. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check64 days agoChange DetectedThere are no significant changes to the study page; only minor visual/textual differences that do not impact the page’s purpose. To avoid being alerted by small changes, set an alert condition by clicking below.SummaryDifference0.2%

- Check93 days agoChange DetectedSummary of changes: updated operating-status notice and a version bump to v3.2.0, replacing the previous v3.1.0.SummaryDifference2%

- Check100 days agoChange Detected- Updated version from v3.0.2 to v3.1.0. - No other content changes detected.SummaryDifference0.1%

Stay in the know with updates to Long-term Safety of Dupilumab in Pediatric AD Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Long-term Safety of Dupilumab in Pediatric AD Clinical Trial page.